Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Tumor type

Solid Tumors

No OncoTree code · 7 articles

Clinical · Molecular biology · Bioinfo & AI

Real-world genomic profiling of solid tumors: validation and clinical insights from a Brazilian cohort

Souza TX, Petroni RC, Lima LB, et al.

Einstein (Sao Paulo, Brazil)

This study details the analytical validation of the Illumina TruSight Oncology 500 (TSO500) assay within a CAP-certified clinical laboratory in Brazil. It also presents real-world findings from Comprehensive Genomic Profiling (CGP) performed on 454 patients with solid tumors. The research highlighted the genomic landscape of these tumors, including the detection of both novel and canonical gene fusions. The analytical performance of the assay was assessed, demonstrating high specificity and positive predictive value. The authors conclude that TSO500 provides crucial insights for diagnosis, prognosis, and treatment decisions in oncology.

Clinical · Molecular biology · Bioinfo & AI

Genomic Landscape of GNAQ and GNA11 Mutations in Metastatic Solid Tumors: A Real-World Data Analysis

Kwon M, Go Y, Shin JE, et al.

JCO precision oncology

This real-world study analyzed the genomic landscape of GNAQ and GNA11 mutations in 5,416 patients with metastatic solid tumors. It revealed that these mutations, while known in uveal melanoma, are also present in other cancers such as colorectal, melanoma, and gastric cancer. An immunogenic subgroup, characterized by non-hotspot mutations and high TMB or MSI, was identified and associated with potential benefit from immune checkpoint inhibitors. Canonical hotspot mutations, conversely, were predominant in TMB-low/MSS tumors. These findings highlight the importance of differentiating driver mutations from bystander mutations to guide therapeutic strategies.

Bioinfo & AI

SOPA and SIMPA: normalized single-sample integrated multiomics pathway analysis of tumor heterogeneity in solid cancers

Alsharoh H, Ismaiel A, Calin GA, et al.

Briefings in bioinformatics

Managing tumor heterogeneity, especially in metastatic cancers, presents a significant challenge. This article introduces SOPA (Single-Omic Pathway Analysis) and SIMPA (Single-sample Integrated Multiomics Pathway Analysis), two bioinformatics pipelines designed for supervised differential pathway analysis at the single-sample level. These tools compare the molecular profile of each sample against a range of predefined controls. They proved more effective than existing methods in identifying sample-specific perturbations and distinct tumor subgroups, particularly concerning immune and metabolic pathway activity, with implications for patient survival.

Clinical · Molecular biology

The dynamic evolution of circulating tumor cells during glecirasib treatment predicts survival and resistance in gastrointestinal tumors with KRASG12C mutation

Jiang L, Luo Y, Liang H, et al.

Human cell

This study investigated the dynamics of circulating tumor cells (CTCs) in 18 patients with advanced KRASG12C-mutated solid tumors treated with glecirasib, a KRASG12C inhibitor. Researchers observed an evolution in CTC subtypes (epithelial, mesenchymal, mixed) during treatment, particularly an increase in mixed CTCs at progression. Baseline CTC levels and their changes correlated with progression-free survival and overall survival. Furthermore, adding local radiotherapy for progressive lesions in patients with more than one CTC at progression significantly prolonged survival.

Clinical · Molecular biology · Bioinfo & AI

Disruption of the structural maintenance of chromosomes 5/6 complex enables tumor mutagenesis

Tran T, Fan J, Zhao X, et al.

NAR cancer

The SMC5/6 complex is crucial for genome stability, with germline variants linked to genomic instability. This pan-cancer analysis demonstrates that deleterious somatic variants in SMC5/6 genes, but not copy number alterations, are associated with an elevated tumor mutational burden (TMB). This mutagenesis is largely attributed to polymerase epsilon dysfunction and mismatch repair deficiency. Patients with these SMC5/6 variants exhibit improved survival, partly due to a superior response to immunotherapy. These findings indicate that SMC5/6 gene status could serve as a prognostic and predictive biomarker for tailored therapeutic strategies.

Clinical · Molecular biology · Bioinfo & AI

Clinical-Grade Somatic Variant Interpretation Performance via a Rule-Constrained Large Language Model Framework (Oncology Logic-Informed Variant Evaluator)

Tjota MY, Wang P, Qin S, et al.

The Journal of molecular diagnostics

This article introduces OLIVE, a rule-constrained large language model (LLM) framework designed for somatic variant interpretation in clinical oncology. The system integrates gene-specific biology, tumor context, and multiple evidence sources to classify variants. Evaluated on 200 clinical next-generation sequencing cases, OLIVE demonstrated a mean concordance of 97.5% with historical laboratory classifications. Observed discordances were primarily attributed to interpretive ambiguity or evolving evidence rather than model instability, and were deemed equally valid by expert adjudication. These findings indicate that OLIVE can reproducibly support expert somatic variant interpretation in a real-world clinical setting.

Molecular biology · Bioinfo & AI

Implementing whole genome and transcriptome sequencing for cancer patients in routine healthcare: a comprehensive guide to costing

Altbürger C, Menzel M, Beck S, et al.

British journal of cancer

This study conducted a detailed micro-costing analysis of implementing whole genome sequencing (WGS) and whole transcriptome sequencing (WTS) in routine clinical care for cancer patients. The primary goal was to identify the key cost drivers hindering the widespread adoption of these comprehensive diagnostic technologies. Researchers developed a multidimensional costing model, which revealed that consumables, particularly flow cells, represent the main expenditure. While personnel and equipment costs decreased with increasing sample volumes, consumable and data processing/storage costs remained largely unchanged. The conclusion emphasizes that falling consumable prices are crucial for broader integration of WGS/WTS as a clinical-grade test.